Abbott: First Smartphone Compatible Insertable Cardiac Monitor

Equities Research  |

An arrhythmia is an abnormal heart rhythm that develops when disease or injury disrupts the heart's electrical signals, causing the heart to beat erratically. Arrhythmias are very common, and nearly everyone will experience an abnormal heart rhythm at some point in their lives. While most arrhythmias are harmless, over 850,000 people are hospitalized annually due to arrhythmias, according to the Dartmouth-Hitchcock Medical Center.

Abbott Laboratories (NYSE: ABT) announced today that it received FDA approval to market its Confirm Rx™ Insertable Cardiac Monitor (ICM), the world's first and only smartphone compatible ICM designed to help physicians remotely identify cardiac arrhythmias and engage with their patients. Readers may recall Abbott's acquisition of St. Jude Medical completed earlier this year; the Confirm RX ICM and myMerlin smartphone app were key assets in that deal.

"Confirm Rx shows what we can do with cutting edge communication technology and the most advanced medical devices that provide new opportunities to improve patient care," said Avi Fischer, MD, divisional vice president and medical director of Abbott's Cardiac Rhythm Management business. "By offering a device that uses Bluetooth wireless technology from the patient's smartphone, we can help physicians easily and remotely diagnose potentially dangerous abnormal heart beats without requiring the patient to use a separate or cumbersome recording device."

Once implanted—just under the skin in the chest during a quick, minimally-invasive outpatient procedure—Confirm Rx continuously monitors heart rhythms to detect a range of cardiac arrhythmias, including irregular heartbeats, or atrial fibrillation. Data collected by the device is then securely transmitted to a patient's physician via the mobile app on a schedule set by the clinic. The app also allows patients to record symptomatic events from their own smartphone without the need for additional hardware such as handheld activators or bedside transmitters.

The Confirm Rx is designed for:

  • Continuous heart monitoring using the patient's smartphone to record episodes of irregular heartbeat.
  • The ability for patients to easily send their heart rhythm information to their doctor without interrupting daily activities.
  • A discreet implant—the slimmest insertable cardiac monitor available today.

The associated myMerlin smartphone app enables patients to track symptoms proactively, sync their data with their clinic at any time and view their transmission history without having to contact their clinic to confirm successful data transfers. The Confirm Rx ICM limits communication to a single authenticated myMerlin mobile app, and all wireless communications are encrypted using the highest standards in mobile security.

Please email us at to see our Case Studies and Testimonials.

Please click here for information on our new trading platform.

Please click here to see our weekly newsletter.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Symbol Name Price Change % Volume
ABT Abbott Laboratories 72.76 0.56 0.78 1,535,615 Trade


Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.